(Q37892300)

24 August 2017

1 reference

title

Recent advances in the treatment of atherogenic dyslipidemia in type 2 diabetes mellitus (English)

1 reference

24 August 2017

0 references

1 reference

1 reference

atherogenic dyslipidemia

1 reference

Christoph Wanner

1

1 reference

24 August 2017

Vera Krane

series ordinal

2

1 reference

24 August 2017

language of work or name

1 reference

21 June 2011

1 reference

Kidney and Blood Pressure Research

24 August 2017

1 reference

24 August 2017

34

1 reference

24 August 2017

4

1 reference

24 August 2017

209-217

1 reference

The impact of pharmaceuticals on the decline of cardiovascular mortality in Germany

24 August 2017

1 reference

Standards of medical care in diabetes--2008.

21 January 2018

1 reference

Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association

21 January 2018

1 reference

21 January 2018

1 reference

Global and societal implications of the diabetes epidemic

21 January 2018

1 reference

Coronary heart disease mortality among young adults in the U.S. from 1980 through 2002: concealed leveling of mortality rates.

21 January 2018

1 reference

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

Effect of a multifactorial intervention on mortality in type 2 diabetes

21 January 2018

1 reference

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

21 January 2018

1 reference

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis

21 January 2018

1 reference

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

21 January 2018

1 reference

Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.

21 January 2018

1 reference

Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey

21 January 2018

1 reference

Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol

21 January 2018

1 reference

21 January 2018

1 reference

Lipoproteins and diabetic microvascular complications

21 January 2018

1 reference

The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient?

21 January 2018

1 reference

Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74.

21 January 2018

1 reference

Serum triglycerides are a predictive factor for the development and the progression of renal and retinal complications in patients with type 1 diabetes

21 January 2018

1 reference

Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS), Early Treatment Diabetic Retinopathy Study Report No. 26.

21 January 2018

1 reference

Determinants of progression of microalbuminuria in patients with NIDDM.A prospective study.

21 January 2018

1 reference

Differing associations of lipid and lipoprotein disturbances with the macrovascular and microvascular complications of type 1 diabetes.

21 January 2018

1 reference

Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy

21 January 2018

1 reference

Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22.

21 January 2018

1 reference

The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid lowering therapy?

21 January 2018

1 reference

Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort

21 January 2018

1 reference

Vascular risk factors and diabetic neuropathy

21 January 2018

1 reference

Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study.

21 January 2018

1 reference

The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program

21 January 2018

1 reference

Statins for improving renal outcomes: a meta-analysis

21 January 2018

1 reference

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.

21 January 2018

1 reference

Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease

21 January 2018

1 reference

Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study

21 January 2018

1 reference

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).

21 January 2018

1 reference

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance

21 January 2018

1 reference

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

21 January 2018

1 reference

Fenofibrate for diabetic retinopathy

21 January 2018

1 reference

Looking to the future: diabetic neuropathy and effects of rosuvastatin on neurovascular function in diabetes models

21 January 2018

1 reference

Statins may be useful in diabetic foot ulceration treatment and prevention

21 January 2018

1 reference

Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study.

21 January 2018

1 reference

Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes

21 January 2018

1 reference

Long-term effects of eicosapentaenoic acid on diabetic peripheral neuropathy and serum lipids in patients with type II diabetes mellitus.

21 January 2018

1 reference

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis

21 January 2018

1 reference

PPAR agonists: multimodal drugs for the treatment of type-2 diabetes

21 January 2018

1 reference

Therapeutic roles of peroxisome proliferator-activated receptor agonists

21 January 2018

1 reference

Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives

21 January 2018

1 reference

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

21 January 2018

1 reference

Risk of adverse events with fibrates

21 January 2018

1 reference

Risk for myopathy with statin therapy in high-risk patients.

21 January 2018

1 reference

Current overview of statin-induced myopathy

21 January 2018

1 reference

Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia

21 January 2018

1 reference

Effects of extended-release niacin on lipoprotein subclass distribution

21 January 2018

1 reference

Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes

21 January 2018

1 reference

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

21 January 2018

1 reference

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

21 January 2018

1 reference

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient

21 January 2018

1 reference

Triglycerides and the Risk of Coronary Heart Disease

21 January 2018

1 reference

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

21 January 2018

1 reference

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000326849

1 reference

release_so2xpgecjncb5pe2szg464t7i4

24 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/so2xpgecjncb5pe2szg464t7i4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference